







Churg Strauss syndrome is a medical
condition of unknown aetiology characterized by asthma,
eosinophilia and finally vasculitis involving small vessels
in the limbs and nasal sinuses and the lungs. The purpose
of this review is to highlight the natural history of this
condition, the pathogenesis, clinical features and
treatment modalities available and the prognosis.
Literature on the subject was reviewed using
manual library search, articles in journals, internet search
and conference abstracts.
Churg Strauss syndrome has been reported to
be predominantly common in middle aged individuals in
their middle age of life with a history of new onset or
worsened asthma. The condition has a male
predisposition. Prior to the advent of steroid therapy this
condition invariably leads to death, but since the
introduction of prednisolone therapy and other
immunosuppressive therapy, the outlook has improved
for sufferers and long term survival has been seen.
Suspicion of this condition should be based
on a good history, physical examination and laboratory
investigations and diagnosis based on the criteria that
has been drawn by the American College of
Rheumatology.
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Introduction
Churg Strauss syndrome is an extremely rare condition
which results from vasculitis of vessels. The inflammation
leads to systemic organ damage chief among them being
the skin, lungs, kidneys, nerves, nasal sinuses, joints,
intestinal tract and the heart . There is almost always a
history of asthma and allergic rhinitis . The inflammation is
accompanied by peripheral blood eosinophilia and tissue
invasion by eosinophils. These changes are seen along
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with granulomatous lesions that appears as vasculitis
on tissue biopsy. The vasculitis can present either as
weakening of the blood vessels leading to formation of
aneurysm and bleeding or to narrowing of vessels to the
point of obliterating such vessels with resultant
blockage and organ damage.
Although CSS is a rare disease, it is however often seen
in clinical practice. Misdiagnosis is due to the clinician
failure to have a high index of suspicion. This has
resulted in many high profile patients seeking treatment
overseas.
This condition was first described by Dr Jacob and Dr
Lotte Strauss in 1951. They described it as a syndrome
consisting of asthma, eosinophilia, fever and an
accompanying vasculitis involving several organ
systems. CSS shares several clinical and pathological
features with another type of vasculitis known as
polyartheritis nodosa (PAN) . Churg and Strauss were
able to identify that this clinical entity differs from PAN
by the presence of granulomas and peripheral blood
eosinophilia. CSS is also known as allergic
granulomatosis .
The cause of CSS is unknown. It is not a form of
malignant condition nor is it contagious. There is no
evidence that CSS is contagious nor for a familiar
inheritance . Evidence from the laboratory has shown
that the immune system plays a key role in the
pathogenesis . An over reactive immune system due to
an unknown stimulus results in immense production of
eosinophils. The granule content of the eosinophils
finally leads to vasculitis which leads to damage of
blood vessels . Recent finding has linked the CSS to the
presence of the antineutrophilic cytoplasmic antibody
(ANCP) and the characteristic vasculitis . However the
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CSS can occur in all age groups from childhood to the
elderly. The average age of patients at the time of
diagnosis is between 35 50 years old. There is a male
predominance in this disoder .
The typical patient with CSS presents with asthma in
100% of patients. Asthma symptoms may begin long
before the onset of vasculitis which may be many years
before any other symptom of CSS arising . Other early
symptoms and signs include nasal polyps and allergic
rhinitis in 61% of patients. There may be anorexia with
loss of weight, fever and myalgias in 50 70% of cases.
The next stage is the finding of an increase number of
eosinophils in the blood usually > 15% and sometimes in
excess of 60%. The final diagnosis in the disease process
is the development of vasculitis which involves the skin,
nose, lungs, nerves and kidneys and other organs .
Involvement of the nerve may result in the devastating
medical condition known as mononeuritis multiplex which
induces severe tingling sensation, numbness, shooting
pains and muscle wasting/ power loss in the hands or feet
in 78% of patients  .
The changes affecting various organs in CSS usually
include the nose, lungs, skin kidney, gastrointestinal tract,
heart and the nerves  . In the nose, sinusitis including
allergic rhinitis and nasal polyps are the main findings .
Figure 1 below shows the changes that occur on the
septum of the nose.
In the lungs, pulmonary infiltrates are seen in 1/3 of
patients. Bleeding into the lungs is occasionally seen,
while diffuse interstitial lung disease is rare  . Pleural
effusions are seen in a third of cases. The effusions may
be exudative and may contain a significant number of
eosinophils  .
Skin changes including rashes and palpable purpura and
nodules above and below the skin are the main picture
seen often at sites of pressure such as the elbows and this
is evident in about 50% of cases. There are palpable
purpuras in 29% of patients while skin nodules and
urticarias are found in 29% and 8% respectively in
affected individuals  . Figure 2 below shows the skin
changes at the elbow.
In the kidneys, glomerulonephritis and hypertension are
the main changes seen and they are found in about 25%
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The gastrointestinal tract is characterized by vasculitic
lesions which are occasionally found while granulomas
are sometimes seen in the spleen  . In the heart
vasculitic lesion can lead to congestive heart failure or
heart failure . Involvement of the nerves are usually
confined to peripheral nervous system and results in
pain, numbness or tingling in the extremities
(neuropathy/ mononeuritis multiplex) .
In addition to a good and detailed history a careful
physical examination will be able to elicit some of the
changes involving various organ systems. Full blood
counts will reveal an increase in the eosinophil count
(see figure 3 below), all other cells may remain normal
or within limit. Chest x ray and other imaging technique
may help to show other changes in the lung  . Nerve
conduction studies and tissue biopsy from skin, lung
and nerve may contribute to the diagnosis  . The ESR is
invariably increased in 90% of individuals and may be
accompanied with mild anaemia. Majority of patients
with CSS appears to have positive antineutophil
cytoplasmic antibody (ANCA) . An increased level of
IgE is indicative of disease severity .
In order to arrive at a diagnosis, theAmerican College of
Rheumatology has established certain criteria that must
be satisfied before classifying anybody as having CSS.
These criteria are designed to differentiate CSS
patients from those having other forms of vasculitis for
example PAN. Not all patients meet all the criteria.
Some may have only 2 or 3 of the criteria and they may
be classified as having CSS. In order to avoid this pitfall,
the American College of Rheumatology selected 6
disease features to help in making a diagnosis and
differentiating CSS from other vasculitides. In other to
make a diagnosis a patient must have at least 4 of the
following criteria  :
1. Asthma
2. Eosinophilia> 10% of differential WBC count
3. Mononeuropathy
4. Transient pulmonary infiltrates on chest x ray
5. Paranasal sinus abnormalities
6. Biopsy of a vessel containing extravascular
eosinophils
Treatment depends on severity symptoms and the
involvement of organ damage. In patients with mild
disease, systemic corticosteroid may be sufficient  .
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vasculitis, cytotoxic therapy must be undertaken with
cyclophosphamide as the drug of choice, although there
are data that appear to suggest that the use of high dose
intravenous steroid therapy may result in remission in
more than 90% of patients. Relapse can occur in 26% of
patients and even with aggressive treatment death has
been described in 25% of patients  . The cause of death in
most patients with CSS was vasculitis related primarily,
affecting the cardiac and mesenteric vessels  .
In general, CSS usually respond to prednisolone. Initially
high doses of oral prednisolone are given in order to
produce remission as quickly as possible. This will entail
giving a start dose of 40 60 mg daily in divided doses form
a period of about a month and then tapering the dose in
the subsequent month depending on the response of this
initial dose. Other immunosuppressive drugs which may
help in the control of this condition include Azathioprine,
Cellcept, Methotrexate or Cyclophosphamide either as
single dose or in combination  . In addition to the regimen
above, intravenous steroid such as methylprednisolone
and plasmapheresis may be used in patients that did not
respond to prednisolone or other immunosuppressive
regimen  .
Prior to the advent of prednisolone, CSS was often a fatal
disease the majority of patients dying from rampant
uncontrolled disease. With present therapy constitutional
symptoms begin to recede quickly with gradual
improvement in cardiac and renal functions as well as
improvement in the pain that results from peripheral
involvement. The course of therapy may last for 1 2
years, although the length and type of treatment depend
on the severity of disease and organ involved. The
patient's response to treatment and continuation of
disease control during lowering of prednisolone dose are
the primary determinate on how long therapy is
continued. Laboratory monitoring of blood tests is very
helpful in gauging the activities of disease. Some of the
most useful laboratory tests are the erythrocyte
sedimentation rate and the WBC count and differentials.
However the five year survival ranges from 62 79% with
morta l i ty st rongly associated wi th cardiac,
gastrointestinal and renal involvement . Nevertheless,
after treatment with corticosteroids, relapses are frequent
in 25% of cases even after recovering from vasculitis
most patients (95%) still have asthma requiring
corticosteroid therapy  .
With the advent of prednisolone CSS, which in the past
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control. However the benefits of steroid and other
immunosuppressive therapy will not mean much if a
proper diagnosis is not reached before the onset of
organ damage. Therefore it is incumbent on physicians
to have a high index of suspicion when the physical
examination and the white cell count are suggestive of
CSS and to institute early treatment.
Figure 1 showing ulceration of the nasal septum
Figure 2 showing a granulomatous lesion on the elbow.
Figure 3 showing the peripheral blood with eosinophilia
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